[PDF][PDF] Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically

TL Putoczki, S Thiem, A Loving, RA Busuttil, NJ Wilson… - Cancer cell, 2013 - cell.com
TL Putoczki, S Thiem, A Loving, RA Busuttil, NJ Wilson, PK Ziegler, PM Nguyen, A Preaudet…
Cancer cell, 2013cell.com
Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives
many of the cancer" hallmarks" through downstream activation of the gp130/STAT3
signaling pathway. However, we show that the related cytokine IL-11 has a stronger
correlation with elevated STAT3 activation in human gastrointestinal cancers. Using genetic
mouse models, we reveal that IL-11 has a more prominent role compared to IL-6 during the
progression of sporadic and inflammation-associated colon and gastric cancers …
Summary
Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer "hallmarks" through downstream activation of the gp130/STAT3 signaling pathway. However, we show that the related cytokine IL-11 has a stronger correlation with elevated STAT3 activation in human gastrointestinal cancers. Using genetic mouse models, we reveal that IL-11 has a more prominent role compared to IL-6 during the progression of sporadic and inflammation-associated colon and gastric cancers. Accordingly, in these models and in human tumor cell line xenograft models, pharmacologic inhibition of IL-11 signaling alleviated STAT3 activation, suppressed tumor cell proliferation, and reduced the invasive capacity and growth of tumors. Our results identify IL-11 signaling as a potential therapeutic target for the treatment of gastrointestinal cancers.
cell.com